Zenicor Medical Systems AB
Zenicor Medical Systems AB (publ), a medical technology company, provides products and solutions for the diagnosis of arrhythmia and stroke prevention. The company offers Zenicor One, a handheld ECG device for arrhythmia; Zenicor Flex, a device that provides ECG data and arrhythmia detection; and Zenicor View, a web-based system solution for all types of arrhythmia investigations. It also provide… Read more
Zenicor Medical Systems AB (ZENI) - Net Assets
Latest net assets as of September 2025: Skr39.53 Million SEK
Based on the latest financial reports, Zenicor Medical Systems AB (ZENI) has net assets worth Skr39.53 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr69.89 Million) and total liabilities (Skr30.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr39.53 Million |
| % of Total Assets | 56.57% |
| Annual Growth Rate | 13.08% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 40.07 |
Zenicor Medical Systems AB - Net Assets Trend (2020–2024)
This chart illustrates how Zenicor Medical Systems AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zenicor Medical Systems AB (2020–2024)
The table below shows the annual net assets of Zenicor Medical Systems AB from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr28.48 Million | -6.82% |
| 2023-12-31 | Skr30.57 Million | +87.53% |
| 2022-12-31 | Skr16.30 Million | -9.68% |
| 2021-12-31 | Skr18.05 Million | +3.61% |
| 2020-12-31 | Skr17.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zenicor Medical Systems AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3035027400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Skr70.87 Million | 248.81% |
| Total Equity | Skr28.48 Million | 100.00% |
Zenicor Medical Systems AB Competitors by Market Cap
The table below lists competitors of Zenicor Medical Systems AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Diamcor Mining Inc
OTCQB:DMIFF
|
$1.13 Million |
|
AIRA Factoring Public Company Limited
BK:AF
|
$1.14 Million |
|
Moab Minerals Ltd
AU:MOM
|
$1.14 Million |
|
K9 Gold Corp
OTCQB:WDFCF
|
$1.14 Million |
|
DCM Financial Services Limited
NSE:DCMFINSERV
|
$1.13 Million |
|
HCW Biologics Inc
NASDAQ:HCWB
|
$1.13 Million |
|
NEXANS - Dusseldorf Stock Exchang
DU:NXS
|
$1.13 Million |
|
Enersize Oy
ST:ENERS
|
$1.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zenicor Medical Systems AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 30,568,370 to 28,484,233, a change of -2,084,137 (-6.8%).
- Net loss of 2,084,137 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-2.08 Million | -7.32% |
| Total Change | Skr- | -6.82% |
Book Value vs Market Value Analysis
This analysis compares Zenicor Medical Systems AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.42x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Skr2.72 | Skr1.32 | x |
| 2021-12-31 | Skr2.81 | Skr1.32 | x |
| 2022-12-31 | Skr2.54 | Skr1.32 | x |
| 2023-12-31 | Skr3.39 | Skr1.32 | x |
| 2024-12-31 | Skr3.16 | Skr1.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zenicor Medical Systems AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.27%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 2.22x
- Recent ROE (-7.32%) is below the historical average (-4.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 8.18% | 7.95% | 0.54x | 1.89x | Skr-316.33K |
| 2021 | 3.48% | 3.20% | 0.49x | 2.24x | Skr-1.18 Million |
| 2022 | -10.72% | -8.13% | 0.47x | 2.82x | Skr-3.38 Million |
| 2023 | -18.28% | -23.13% | 0.40x | 1.97x | Skr-8.64 Million |
| 2024 | -7.32% | -8.27% | 0.40x | 2.22x | Skr-4.93 Million |
Industry Comparison
This section compares Zenicor Medical Systems AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $75,200,026
- Average return on equity (ROE) among peers: -74.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zenicor Medical Systems AB (ZENI) | Skr39.53 Million | 8.18% | 0.77x | $1.13 Million |
| Acarix A/S (ACARIX) | $76.60 Million | -60.65% | 0.08x | $28.86 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $8.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $353.18 Million | -39.18% | 0.87x | $19.20 Million |
| CellaVision AB (CEVI) | $20.07 Million | 13.08% | 1.20x | $262.59 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $65.69 Million | -72.50% | 0.20x | $13.78 Million |
| Chordate Medical Holding AB (CMH) | $38.95 Million | -55.88% | 0.13x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $93.64 Million | 22.63% | 0.57x | $56.67 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $41.40 Million | -170.53% | 0.39x | $5.40 Million |